Sofinnova Investments’s PDS Biotechnology PDSB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-142,635
Closed -$418K 81
2024
Q2
$418K Hold
142,635
0.02% 77
2024
Q1
$565K Hold
142,635
0.03% 64
2023
Q4
$709K Hold
142,635
0.04% 54
2023
Q3
$720K Hold
142,635
0.05% 58
2023
Q2
$717K Hold
142,635
0.05% 45
2023
Q1
$877K Hold
142,635
0.06% 49
2022
Q4
$1.88M Hold
142,635
0.11% 47
2022
Q3
$424K Hold
142,635
0.02% 57
2022
Q2
$521K Hold
142,635
0.04% 56
2022
Q1
$883K Hold
142,635
0.07% 55
2021
Q4
$1.16M Hold
142,635
0.07% 67
2021
Q3
$2.13M Hold
142,635
0.13% 64
2021
Q2
$1.79M Hold
142,635
0.1% 65
2021
Q1
$649K Hold
142,635
0.04% 64
2020
Q4
$305K Hold
142,635
0.02% 67
2020
Q3
$332K Hold
142,635
0.02% 67
2020
Q2
$287K Hold
142,635
0.02% 76
2020
Q1
$104K Hold
142,635
0.01% 64
2019
Q4
$378K Hold
142,635
0.03% 59
2019
Q3
$482K Hold
142,635
0.04% 71
2019
Q2
$854K Hold
142,635
0.08% 69
2019
Q1
$1.05M Sell
142,635
-1
-0% -$8 0.1% 61
2018
Q4
$916K Hold
142,636
0.11% 57
2018
Q3
$2.34M Hold
142,636
0.21% 50
2018
Q2
$2.94M Hold
142,636
0.33% 47
2018
Q1
$3.37M Buy
+142,636
New +$38.4M 0.58% 15

Other funds holding PDSB

Sofinnova Investments's PDSB Position: Q3 2024 in Review

Sofinnova Investments sold out of PDS Biotechnology (PDSB) in Q3 2024, closing a stake of 142,635 shares — an estimated $418K sold.

Sofinnova Investments first reported a position in PDSB in Q1 2018 and held it in 26 quarters. The position peaked at $3.37M in Q1 2018. 57 funds tracked by Wall St. Rank hold PDSB as of Q3 2024.

  • Sofinnova Investments reported no remaining PDS Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Sofinnova Investments sold 142,635 PDS Biotechnology shares in Q3 2024, an estimated $418K.
  • Sofinnova Investments first reported a position in PDS Biotechnology in Q1 2018 and held it in 26 quarters.
  • Sofinnova Investments's PDS Biotechnology position peaked at $3.37M in Q1 2018.
  • 57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2024.

Based on Sofinnova Investments's 13F filing for Q3 2024, filed 13 Nov 2024.